Celltrion Inc
068270
Company Profile
Business description
Founded in 2002 in South Korea, Celltrion is one of the largest biosimilar manufacturers around the world. Biosimilar drug sales accounted for 87% of its total revenue in 2024. Europe is the largest market for its biosimilar drug sales, contributing more than 47% of its total revenue, followed by 37% from the North America region and 16% from emerging markets. Besides biosimilar manufacturing, Celltrion entered the contract manufacturing business in 2024.
Contact
13-6 SongDo-Dong
Yeonsu-gu
Incheon City406-840
KORT: +82 32855000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,916
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
We plan to raise our fair value estimate of Coca-Cola stock.
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.10 | 10.80 | -0.12% |
| CAC 40 | 8,218.34 | 40.52 | -0.49% |
| DAX 40 | 24,250.08 | 79.95 | -0.33% |
| Dow JONES (US) | 46,805.29 | 119.45 | -0.25% |
| FTSE 100 | 9,533.18 | 106.19 | 1.13% |
| HKSE | 25,781.77 | 245.78 | -0.94% |
| NASDAQ | 22,931.87 | 21.79 | -0.09% |
| Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
| NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
| S&P 500 | 6,733.32 | 2.03 | -0.03% |
| S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
| SSE Composite Index | 3,913.76 | 2.57 | -0.07% |